UK Invests £9.3 Million in Future-Ready Medicine Manufacturing Labs

Innovate UK funds advanced technologies like AI and robotics to create highly efficient, data-driven pharmaceutical development and manufacturing.

Generic image of a futuristic laboratory with robotic automation and digital interfaces.
AI

Generic image of a futuristic laboratory with robotic automation and digital interfaces.

The UK is set to revolutionise medicine development and manufacturing with a £9.3 million investment in 'labs of the future', integrating automation, robotics, AI, and connectivity.

This significant investment, channelled through Innovate UK’s Transforming Medicines Manufacturing Innovation programme, aims to transition from traditional manual laboratory environments to highly efficient, intelligent, and data-driven facilities. The initiative seeks to accelerate research, development, and the manufacture of medicines, enabling laboratories to operate autonomously 24/7.
The funding underscores Innovate UK’s commitment to fostering business innovation that enhances UK competitiveness, boosts productivity, and drives long-term economic growth. The programme supports a diverse range of technologies, including next-generation smart platforms for radiopharmaceuticals and synthetic DNA production, as well as AI-enabled labs focused on accelerating the development and formulation of medicines, cancer therapies, manufacturing processes, and scientific decision-making.
Further support is directed towards decentralised cell and gene therapy manufacturing, the application of robotics, wearable technologies, and the use of manufacturing data to improve pharmaceutical efficiency, quality, scalability, and overall productivity.
Hareklea Markides, Innovation Lead for Medicines Manufacturing at Innovate UK, highlighted the programme's role in showcasing UK innovation. "By combining expertise in life sciences, advanced manufacturing and digital technologies, these businesses are developing solutions that could transform medicines development and manufacturing, further strengthening the UK’s global competitiveness," she stated.
Several projects are set to benefit, including Allos AI developing an AI-guided automated laboratory for faster medicine improvement, Astral Neutronics enhancing UK radiopharmaceutical capability, and Danu Insights creating an AI-driven automated lab for affordable cell-based cancer therapies. Other initiatives include FourPlus Immersive's AI system for operator support, ID Health's AI and robotics platform for personalised medicine, Implexis's automated platform for patient-friendly medicines, NunaBio's synthetic DNA manufacturing platform, and Ori Biotech's decentralised model for cell and gene therapy manufacturing.
Based on information from the official source: Medical Research Council (17/11/2026)